Treatment Overview

The ALL treatment that a patient receives depends on a number of factors, for example, age, other co-existing medical conditions and the specific type of ALL that the person is suffering from.

Patients who are “fit” (no prior significant medical conditions) and under 70 years old are usually given intravenous (IV) chemotherapy, which requires hospitalisation for 3–4 weeks (or more in case of treatment-related complications). Older and/or more “frail” patients (patients with serious prior medical conditions) may be given other treatment options, such as subcutaneous (applied under the skin) or oral (taken by the mouth) therapies.

Watch the videos in this section to learn more about various treatment options available for ALL and to gain a better understanding of how to best approach your doctors with treatment questions.

 

Videos

Inside the First FDA-Approved CAR-T Cell Therapy

ALL patients who haven’t responded to standard care have new options on the horizon, including a type of immunotherapy called CAR T-cell therapy. Learn more from Dr. Michael Deininger.

Published:

How should we treat immature B-cell ALL (Burkitt's disease)?

How should we treat immature B-cell ALL (Burkitt's disease)?

Published:

Advertisement
tritt unserer Gemeinschaft bei Registrieren Sie sich für Veranstaltungen Lesen Sie unseren neuesten Blog
Advertisement

Page last updated on April 3, 2017